MSL
ALXN

Mackay Shields LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Mackay Shields LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,871
Closed -$6.41M – 722
2021
Q2 		$6.41M Sell
34,871
-1,705
-5% -$293K 0.06% 284
2021
Q1 		$5.59M Sell
36,576
-39,424
-52% -$6.1M 0.04% 449
2020
Q4 		$11.9M Sell
76,000
-130,512
-63% -$16.8M 0.08% 274
2020
Q3 		$23.6M Buy
206,512
+96,674
+88% +$10.4M 0.16% 134
2020
Q2 		$12.3M Buy
109,838
+47,998
+78% +$5.1M 0.1% 239
2020
Q1 		$5.55M Buy
61,840
+6,042
+11% +$593K 0.05% 371
2019
Q4 		$6.04M Sell
55,798
-4,041
-7% -$432K 0.04% 426
2019
Q3 		$5.86M Buy
59,839
+9,183
+18% +$1.04M 0.04% 452
2019
Q2 		$6.63M Buy
50,656
+1,538
+3% +$198K 0.05% 436
2019
Q1 		$6.64M Buy
49,118
+4,615
+10% +$574K 0.05% 420
2018
Q4 		$4.33M Buy
+44,503
New +$5.26M 0.04% 501
2018
Q3 		– Sell
-48,383
Closed -$6.01M – 1264
2018
Q2 		$6.01M Sell
48,383
-2,874
-6% -$336K 0.04% 439
2018
Q1 		$5.71M Buy
+51,257
New +$6.13M 0.04% 474

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Mackay Shields LLC's ALXN Position: Q3 2021 in Review

Mackay Shields LLC sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 34,871 shares — an estimated $6.41M sold.

Mackay Shields LLC first reported a position in ALXN in Q1 2018 and held it in 13 quarters. The position peaked at $23.6M in Q3 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mackay Shields LLC reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 34,871 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.41M.
  • Mackay Shields LLC first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 13 quarters.
  • Mackay Shields LLC's Alexion Pharmaceuticals position peaked at $23.6M in Q3 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mackay Shields LLC's 13F filing for Q3 2021, filed 12 Nov 2021.